GenePOC announces FDA clearance of its molecular diagnostic test for the detection and differentiation of the five most frequent gene sequences associated with carbapenem-non-susceptibility.
Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays.
Read the press release of Meridian here.
Read the press release of Debiopharm here.
GenePOC Inc., member of the Debiopharm Group, announces its third test to be CE marked, the GenePOC Carba assay, to be used with the revogene device.
GenePOC will participate in the 29th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) from April 13th to 16th, in Amsterdam, Netherlands.
Come to meet us at booth #1.54 and discover the revogene and the tests available for molecular detection of infectious diseases.
GenePOC Inc., member of the Debiopharm Group™, is proud to announce its third test cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene™ device.
Come visit our booth # Z3 C33 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Read the entire Genomeweb interview to learn more on GenePOC’s vision, future SMRT Panels (Specific, Medically
appropriate, Reimbursement appropriate Test) in alignment with the Palmetto decision, and User experience comments on revogene benefits and competitive advantages.
Come visit our booth #1629 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
Come visit our booth #1204 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.